$36.95
1.243.46%
Last update: 3:34 PM
15 minutes delayed
Comments
Loading...
AnaptysBio
ANABNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
AnaptysBio (NASDAQ:ANAB) Stock, Analyst Ratings, Price Targets, Forecasts
AnaptysBio Inc has a consensus price target of $47.07 based on the ratings of 15 analysts. The high is $80 issued by Piper Sandler on February 16, 2024. The low is $21 issued by UBS on November 2, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JP Morgan, and Wedbush on July 22, 2024, July 19, 2024, and May 10, 2024, respectively. With an average price target of $52.67 between HC Wainwright & Co., JP Morgan, and Wedbush, there's an implied 45.37% upside for AnaptysBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Wedbush
Leerink Partners
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for AnaptysBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | 51.81% | HC Wainwright & Co. | Emily Bodnar | → $55 | Initiates | → Buy | Get Alert |
| 07/19/2024 | Buy Now | 90.45% | JP Morgan | Anupam Rama | $29 → $69 | Upgrade | Neutral → Overweight | Get Alert |
| 05/10/2024 | Buy Now | -6.16% | Wedbush | David Nierengarten | → $34 | Reiterates | Outperform → Outperform | Get Alert |
| 04/16/2024 | Buy Now | 29.73% | Leerink Partners | David Risinger | → $47 | Initiates | → Outperform | Get Alert |
| 04/11/2024 | Buy Now | 54.57% | Wells Fargo | Derek Archila | → $56 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | -22.72% | JP Morgan | Anupam Rama | $30 → $28 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | — | Wedbush | David Nierengarten | $20 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 02/26/2024 | Buy Now | 51.81% | BTIG | Julian Harrison | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2024 | Buy Now | 38.01% | Stifel | Alex Schwartz | → $50 | Initiates | → Buy | Get Alert |
| 02/16/2024 | Buy Now | 120.81% | Piper Sandler | Yasmeen Rahimi | → $80 | Initiates | → Overweight | Get Alert |
| 11/29/2023 | Buy Now | -44.8% | Wedbush | David Nierengarten | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 11/03/2023 | Buy Now | -44.8% | Wedbush | David Nierengarten | $18 → $20 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | -42.04% | UBS | Eliana Merle | $28 → $21 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | -28.24% | Wedbush | David Nierengarten | $29 → $26 | Maintains | Neutral | Get Alert |
| 05/22/2023 | Buy Now | -17.2% | JP Morgan | Anupam Rama | $31 → $30 | Upgrade | Underweight → Neutral | Get Alert |
| 05/12/2023 | Buy Now | -19.96% | Wedbush | David Nierengarten | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 24.21% | Guggenheim | Yatin Suneja | $44 → $45 | Maintains | Buy | Get Alert |
| 04/12/2023 | Buy Now | -14.44% | JP Morgan | Anupam Rama | $32 → $31 | Maintains | Underweight | Get Alert |
| 01/06/2023 | Buy Now | — | Raymond James | Timur Ivannikov | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/18/2022 | Buy Now | -11.68% | JP Morgan | Anupam Rama | $24 → $32 | Maintains | Underweight | Get Alert |
| 11/09/2022 | Buy Now | 4.89% | Raymond James | Steven Seedhouse | $30 → $38 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | — | Guggenheim | Yatin Suneja | — | Upgrade | Neutral → Buy | Get Alert |
| 09/19/2022 | Buy Now | -3.39% | HC Wainwright & Co. | Gobind Singh | → $35 | Assumes | → Buy | Get Alert |
| 09/13/2022 | Buy Now | -22.72% | Truist Securities | John Lee | $50 → $28 | Downgrade | Buy → Hold | Get Alert |
| 09/01/2022 | Buy Now | -3.39% | Raymond James | Steven Seedhouse | → $35 | Initiates | → Outperform | Get Alert |
| 03/22/2022 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 03/08/2022 | Buy Now | 26.97% | HC Wainwright & Co. | Michael King | $43 → $46 | Maintains | Buy | Get Alert |
FAQ
What is the target price for AnaptysBio (ANAB) stock?
The latest price target for AnaptysBio (NASDAQ:ANAB) was reported by HC Wainwright & Co. on July 22, 2024. The analyst firm set a price target for $55.00 expecting ANAB to rise to within 12 months (a possible 48.87% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AnaptysBio (ANAB)?
The latest analyst rating for AnaptysBio (NASDAQ:ANAB) was provided by HC Wainwright & Co., and AnaptysBio initiated their buy rating.
When was the last upgrade for AnaptysBio (ANAB)?
The last upgrade for AnaptysBio Inc happened on July 19, 2024 when JP Morgan raised their price target to $69. JP Morgan previously had a neutral for AnaptysBio Inc.
When was the last downgrade for AnaptysBio (ANAB)?
The last downgrade for AnaptysBio Inc happened on January 6, 2023 when Raymond James changed their price target from N/A to N/A for AnaptysBio Inc.
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating AnaptysBio (ANAB) correct?
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a initiated with a price target of $0.00 to $55.00. The current price AnaptysBio (ANAB) is trading at is $36.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.